Transaction · 0001493152-25-003213

Pershing Edward

Pershing Edward, CEO, reported a transaction classified as grant at PROVECTUS BIOPHARMACEUTICALS, INC.. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
Filing timeJan 22
Trade dateJan 16, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

PVCT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PVCT since 2025-01-22Filed 594 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001493152-25-003213
8% Unsecured Convertible Promissory Note
Transaction date
Jan 16, 2025
Filed Jan 22, 2025, 08:57 PM · 6d delay
Shares
—
$0 per share
Estimated value
—
Computed from shares × price
Holdings after
—
Direct

Filing warnings

Notes recorded with this filing
2 warnings
delayed filingThe filing was reported 6 calendar days after the transaction date.
missing sharesThe filing did not provide usable transaction shares.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Delayed Filing Derivative Transaction Direct Ownership
-24score
Filing-only score

-24

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into…

  2. F2

    Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically conv…

Original filing · 0001493152-25-003213
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PVCT